than the rest of the population of the Registre de Malats Renals de Catalunya. These observations call Purpose of study. In recent years, a progressive increase in the need of renal replacement therapy has been for the institution of primary or secondary prevention. noted for patients with diabetes mellitus. The present
modes of treatment, and (iv) the rate of death compared to non-diabetic patients on renal replacement Diabetic nephropathy (DN ) is a microangiopathic therapy and in the general population. complication which has a major impact on the health Results. Of the 936 diabetic patients starting renal system and which afflicts more than one-third of replacement therapy during the period 1984-1994, patients with insulin-dependent diabetes (IDDM ) [1] 24.8% were classified as DN and IDDM, 65.7% as DN and a less well defined proportion (~20%) of diaand NIDDM, and in 9.5%, diabetes accompanied renal betic patients with non-insulin-dependent diabetes failure from standard primary renal disease. The incid-(NIDDM ) [2] . Once DN has set in, it will inexorably ence of diabetic patients has increased from 3 per progress to end-stage renal failure [3] , at least without million population (pmp) in 1984 to 26.6 pmp in 1994.
treatment. Its very presence is a major risk factor for At any given age the risk of requiring renal replacement cardiovascular death [4] . This fact explains why mortherapy with diabetes was 1.5-fold higher in males than bidity and mortality in patients with DN is higher than in females. Of diabetic patients who were <45 years in non-diabetic patients with renal replacement therapy of age, 55% received a renal transplant and >50% (RRT ) [5] . lived with a simultaneous kidney/pancreas graft. For
The proportion of the types of diabetes varies diabetic patients above this age, haemodialysis was the according to genetic background and geography [6 ] . most prevalent form of treatment. Morbidity in diaIn Northern Europe and in the UK, DN in patients betic patients was higher than in the overall RMRC with IDDM is more frequent than in other countries population. Cardiac and vascular disease were the [7] . In contrast, in Central and Southern Europe, the most prominent complications. Mortality of diabetic overwhelming majority of uraemic patients reaching patients on renal replacement therapy was twice that end-stage renal failure suffer from NIDDM which of the overall population of RMRC and 16-fold higher appears to predominate particularly in Mediterranean than in the general population of Catalunya. The risk countries [8] . of death increased with age and was higher in patients
In the recent past, the majority of registries docuwith reduced functional autonomy. Transplanted mented a progressive increase of diabetic patients on patients had a smaller risk than patients on haemodia-RRT. The magnitude of this increase varies, being lysis or CAPD. Survival has increased for patients highest in USA, Japan and Scandinavia, where DN starting treatment after 1990 compared to the period has become the most frequent cause of end-stage renal 1984-1989. failure [9] [10] . The aetiology of end-stage renal failure Conclusion. In conclusion, diabetes mellitus is one of in diabetes is not uniform. The diagnosis of DN is a the main causes leading to renal replacement therapy diagnosis of exclusion and systematic renal biopsy is in Catalunya. Diabetic patients are more multimorbid not practiced. DN is a most frequent cause of endstage renal failure in diabetes mellitus and in >80% Correspondence and offprint requests to: Montserrat Clèries, Registre of IDDM patients this is the correct diagnosis. It must with 'associated diabetes' were categorized patients in whom patients reach end-stage renal failure for causes other the cause of end-stage renal failure was some primary renal than DN [8, 11] (iv) the rate of death compared to non-diabetic patients of the RMRC and of the general population.
Results

Subjects and methods
Of the 5875 patients starting RRT in Catalunya between 1984 and 1994, 936 (15.9%) had diabetes diabetes' increased from 16 to 40 ( Figure 1 ). As of The EDTA codes were used to categorize the type of December 31 1994, the prevalence of patients with nephropathy. Standard nephropathy are primary nephro-diabetes on RRT was 590 (98.3 pmp), whereas that of pathies of glomerular, hereditary, interstitial or unknown non-diabetic patients was 4727 (780.1 pmp).
origin. Patients were categorized as suffering from IDDM if
The aetiology of the renal insufficiency in patients diabetes began before age 30 and was treated with insulin classified as 'associated diabetes' was: ischaemic during the first year of the disease. In such patients, the time nephropathy in 31.4%, unknown in 24.4%, glomerular interval between star of diabetes and beginning of RRT does in 22.1%, interstitial in 14%, adult polycistic kidney not exceed 25 years [13] . The other patients with DN were disease in 3.5%, and other causes in 4.7%.
categorized as NIDDM. We are well aware of the potential of misclassification when adopting this definition as patients
In all types of diabetes, the male gender predomin- ates. The male/female ratio was 1.9 in IDDM, 1.2 in period. The prevalence of ischaemic heart disease increased from 16% to 35%, the prevalence of cerebrov-NIDDM and 2.3 in 'associated diabetes'. The risk of end-stage renal failure for the diabetic male was 1.5-ascular disease and cardiomyopathy increased by a factor of 3. In contrast, the prevalence of hepatic and fold greater and this risk increases with age ( Figure  2 ). The mean age at the beginning of RRT is gastrointestinal disease increased more than 2-fold ( Figure 4 ). 43.6 years for IDDM, 66.4 for NIDDM and 66.9 for patients with 'associated diabetes'. The greatest In 1994, 44.7% of diabetic patients required hospitalization (vs 26.7% of non-diabetic patients). IDDM number of diabetic patients starting on RRT was found in the group of NIDDM between 65 and 74 patients on HD required a greater mean number of hospitalizations (13.1 days) compared to NIDDM on years.
In the population alive on December 31 1994, CAPD (12.1 days), whereas transplanted diabetics were hospitalized for a mean of 4.4 days. haemodialysis was the main form of treatment followed by renal transplantation and CAPD. Compared to the Approximately 80% of diabetic patients were able to take care of themselves; normal or near normal overall RMRC population [15], more diabetic patients were HD (72.8% vs 60%) and CAPD (5.5% vs 2%) functional autonomy was reported in 50% (vs 80% in non-diabetic patients). More than 90% of patients and less were transplanted (21.6% vs 35%). Of all IDDM patients, 37% were alive with a functioning living with a transplant had normal or near normal functional autonomy. The proportion was only 50% transplant. For those below age 45 years, this figure was 55% (of whom more than half had a simultaneous in patients on HD or CAPD.
The survival in diabetic patients was poorer than in kidney/pancreas graft). Only 3% of NIDDM patients received a graft. The different types of treatment vary non-diabetic patients on RRT ( Table 1, Figure 5) .
Survival was slightly better in haemodialysed than according to the time on RRT (Figure 3) . The proportion treated by CAPD is higher initially and sub-CAPD-treated patients ( Table 1 ). Transplanted nondiabetic patients have 10-15% better survival (graft sequently diminishes progressively. Beginning in the second year, the number of transplanted patients and patient survival ) compared to diabetic patients ( Table 1, Figure 6 ). With respect to transplantation of increases. The greatest proportion of patients with a simultaneous kidney and transplant is found between the kidney alone ( TxR) and simultaneous kidney/ pancreas transplantation ( TxRP), patient survival was the first and the fifth year. In the seventh year of RRT, 60.4% of patients were on HD, 34.4% were alive with better for TxR and graft survival for TxRP ( Table 1, Figure 7 ). a transplant and 4.2% remained on CAPD.
At the beginning of RRT, diabetic patients had an In the first year on RRT, mortality was higher by a factor of 2 in diabetic patients compared to the nonaverage of 0.83 associated diseases (0.4 for IDDM and 1.0 for NIDDM ). The proportion increased for all diabetic patient population on RRT and by a factor of 16 compared to the Catalonian general population disease categories with duration of RRT. Amongst patients alive at December 31 1994, the mean number [15] . Although mortality in diabetic patients above 75 years of age was highest (317 per 1000 patients), it of associated diseases was 2.74 (vs 1.65 for non-diabetic patients with standard renal disease). Arterioccclusive was only 1.3-fold higher than in non-diabetic patients of the same age on RRT. In contrast, mortality of disease was present in 18% of diabetic patients at the beginning of RRT and in 66% at the end of the study diabetic patients, age 25-34 years (118 per 1000 patients) was 12.7-fold higher than that of non-diabetic siderably in Catalunya as in other Western countries [10] . In Catalunya the admission of patients for renal patients of the same age on RRT (Figure 8) .
replacement therapy has practically doubled in the The risk of death was 2.4-fold higher in patients period [1984] [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] . Amongst these, the number of with DN than in patients with glomerulonephropathy patients presenting with diabetic nephropathy has [15] adjusted for age, gender, functional autonomy, tripled, i.e. from 8 pmp to 18.9 pmp. Currently, diabetic and comorbidity. Table 2 shows the result of multivarinephropathy represents the second most frequent cause ate analysis, using a proportional hazard model of of renal failure in the population of RMRC, i.e. 18%. Cox, for diabetic patients at the start of RRT. The Although these figures are less than those observed in risk of death increased with age, with loss of functional the USA, i.e. 77 pmp in 1992 [9], and in certain autonomy, was higher on dialysis than after transpopulations of Germany, i.e. 52 pmp in the Neckar plantation, was higher for patients who started RRT region [16 ], they are comparable with the figures before 1990, and showed no statistically significant obtained in neighbouring countries such as Portugal, differences between the genders.
France, and Northern Italy [7, 17] . Our data are further in good agreement with those reported from Badajoz,
Discussion
a community in the south of Spain, where the incidence of diabetic patients on renal replacement therapy was In the past decade, the number of diabetic patients estimated to be 23.3 pmp [18]. The overall incidence of renal patients in the USA is virtually double than entering renal replacement therapy has increased con- [20] reported that the proportion of diabetics on renal replacement therapy pmp in 1994 [9] . When one compares the rate in different registries, one must take into consideration is a reflection of demography of diabetes mellitus in the general population. The present study documents whether all patients have been truly registered. Whereas the RMRC and the United States Renal Data System that NIDDM is mainly responsible for the increment of the number of diabetic patients admitted for renal ( USRDS ) register virtually all patients admitted for renal replacement therapy (or in the case of the USA replacement therapy in Catalunya. The prevalence of NIDDM in Catalunya amongst citizens >64 years, is those beyond the third month of treatment), this is not the case for the EDTA Registry data from Portugal, 8.95% [21] , whereas in the USA for individuals >50 years it is 28% [22] and in Germany for individuals France, or Italy. Their response rate to the EDTA registry was 63%, 61%, and 54%, respectively in 1994, aged 60-69 years it is 13.5%, and individuals >70 years it is 23% [23] . Not unexpectedly, this will result suggesting major underestimation of the true incidence [19] .
in a greater proportion of diabetic patients amongst those admitted for renal replacement therapy. Finally, Another factor accounting for differences in the incidence of ESRF from diabetic nephropathy are the difference between our results and those of the Lombardy Registry, i.e. in 1992 10.4 diabetic patients differences in the prevalence of diabetes mellitus pmp admitted for renal replacement therapy, could be caught on in Catalunya and is utilized in <3% of patients. However, a frequent indication are vascular explained by the greater prevalence of diabetic patients in Catalunya [21] compared to Lombardy [17] . The access problems [15] . During the period [1985] [1986] [1987] [1988] [1989] utilization of CAPD reached its peak, but it was not respective incidence figures for IDDM in Catalunya (i.e. 11.5 per 100 000 inhabitants, aged 0-14 years vs used in >8% of patients. Renal transplantation is the second most common form of renal replacement 6.63 per 100 000 inhabitants in Lombardy) are higher as are those for NIDDM, i.e. known prevalence in therapy in diabetic patients, although only 22% of patients survive with a functioning graft vs 43% of Catalunya of 8.95% equivalent to~15% of known plus non-diagnosed cases vs 10.6% of known plus non-non-diabetic patients on renal replacement therapy.
The proportion of diabetic patients on the waiting list diagnosed cases in Lombardy.
In Catalunya, haemodialysis is the main form of does not exceed 30% and the proportion of patients excluded for medical reasons exceeds that of the rest treatment administered to diabetic patients >45 years of age. CAPD is the most frequent modality of treat-of RMRC patient population. Nevertheless if one studies in more detail the group of patients who ment in countries such as Australia, UK, or Canada [24] . In contrast, this modality of treatment has not received a graft, one notes that transplantation is the principal form of treatment for those <45 years of from Minessota [27] . Nevertheless the figures are less than those reported by others, where only 23% of age (of whom more than half live with a simultaneous kidney and pancreas graft) and that the percentage of diabetic patients were able to care for themselves [14] .
The degree of functional autonomy is related to the transplanted patients amongst IDDM patients is 37%, the figure similar to the non-diabetic patients in type of treatment. It is normal or virtually normal in 95% of patients living with a functioning transplant, RMRC. For the group aged 45-64 years, the proportion receiving a graft is 30%. In contrast, only 3% of but is only normal in 45% of patients on haemodialysis of CAPD. It must not be forgotten, however, that the NIDDM patients live with a graft and this figure is unlikely to increase in these population of elderly former group comprises younger patients with less comorbidity. patients with high comorbidity.
Apart from the increase in the number of patients, Survival of the diabetic patients is worse than for non-diabetic patients on renal replacement therapy and another major component for the impact on the health system caused by diabetic patients results from their this is true for all treatment modalities. The figures noted in this study are similar to those reported from high rate of comorbidity. At the time when renal replacement therapy is started, practically half of the other European Registries [17, 28] and better than those reported from the USA [9] . The survival curve patients with IDDM and all patients with NIDDM have one or more associated diseases and this number is better for patients on haemodialysis than on CAPD.
The difference is in 10% in the third and 5% in the increases considerably during the period they remain on renal replacement therapy. The diabetic patients fifth year of treatment. Analysis of the cases who have received a transplant shows worse results in diabetic are the group with the greatest number of comorbid conditions (average 2.74 vs. 1.65 in non-diabetic patients compared to non-diabetic patients of RMRC. This is true for patient survival and for graft survival. patients). Although all types of comorbid conditions increase in prevalence during replacement therapy, Simultaneous kidney and pancreas transplantation is a therapeutic modality which is on the increase, vascular disease plays a major role. In their pathogenesis, advanced glycation endproducts (AGE ), a novel although it remains somewhat controversial, and some authors consider it still being in its experimental phase form of middlemolecules, appear to play a pathogenic role by interacting with endothelial cells [25, 26 ] . [29] . The results obtained in IDDM patients who received a double graft are comparable to those from Peripheral vascular disease progresses most markedly: it is present in <20% of patients at the beginning of other Registries [30] . If one compares the results of double transplantation with renal transplantation treatment and affects >66% during renal replacement therapy. The prevalence is similar in both types of alone, it is obvious that in patients with simultaneous kidney and pancreas transplantation survival rates are diabetes.
In view of such high comorbidity it is not surprising less than in recipients of a renal graft alone, although graft survival is better. that patients with diabetes mellitus are the group with least functional autonomy in the RMRC: functional Multivariate analysis using the Cox model documents that in patients with diabetic nephropathy morcapacity is limited in 50% compared to 20% in nondiabetic patients. Similar figures have been reported tality is three times higher compared to non-diabetic
